value-of-information techniques assess the expected costs of uncertainty surrounding a decision made on the basis of current information, in order to determine whether further research should be conducted and how this should be designed.
Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||07/10/2020|
|Rapid review completed||22/10/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with obinutuzumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||27/10/2020|
|Pre-submission consultation with Applicant||30/11/2020|
|Full submission received from Applicant||05/02/2021|
|Current Status||Full submission received from Applicant|